思思热在线视频精品,久久香蕉综合色一综合色88,欧美巨大巨粗黑人性aaaaaa

^{<thead id="lbc93"><rt id="lbc93"></rt></thead>}

LOADING IMAGES

齊德巴坦, 齊達巴坦，齊特巴坦，WCK 5107

CAS號	1436861-97-0
規格	0.5g/包	純度	≥98%
貨號	WTM-03-00	貨期	需咨詢
品牌	河北唯特醫藥科技	庫存	20g
規格	0.5g/包
純度	≥98%
貨號	WTM-03-00
貨期	---
品牌	河北唯特醫藥科技
庫存	20g
注意：請務必與賣家聯系核實單價庫存，以確保您的資金安全及交易順利。
參考價：￥8500.00 元/包

立即詢盤

貨號	品牌	純度	規格	參考價	貨期
WTM-03-00	河北唯特醫藥科技	≥98%	0.5g/包	￥8500.00元/包	---

產品詳情

詳細信息(中文)：
齊德巴坦為新型β內酰胺酶抑制劑。目前處于三期臨床試驗階段。

詳細信息(英文)：
Zidebactam and WCK 5153 are novel β-lactam enhancers that are bicyclo-acyl hydrazides (BCH), derivatives of the diazabicyclooctane (DBO) scaffold, targeted for the treatment of serious infections caused by highly drug-resistant Gram-negative pathogens. In this study, we determined the penicillin-binding protein (PBP) inhibition profiles and the antimicrobial activities of zidebactam and WCK 5153 against Pseudomonas aeruginosa, including multidrug-resistant (MDR) metallo-β-lactamase (MBL)-producing high-risk clones. MIC determinations and time-kill assays were conducted for zidebactam, WCK 5153, and antipseudomonal β-lactams using wild-type PAO1, MexAB-OprM-hyperproducing (mexR), porin-deficient (oprD), and AmpC-hyperproducing (dacB) derivatives of PAO1, and MBL-expressing clinical strains ST175 (blaVIM-2) and ST111 (blaVIM-1). Furthermore, steady-state kinetics was used to assess the inhibitory potential of these compounds against the purified VIM-2 MBL. Zidebactam and WCK 5153 showed specific PBP2 inhibition and did not inhibit VIM-2 (apparent Ki [Kiapp] > 100 μM). MICs for zidebactam and WCK 5153 ranged from 2 to 32 μg/ml (amdinocillin MICs > 32 μg/ml). Time-kill assays revealed bactericidal activity of zidebactam and WCK 5153. LIVE-DEAD staining further supported the bactericidal activity of both compounds, showing spheroplast formation. Fixed concentrations (4 or 8 μg/ml) of zidebactam and WCK 5153 restored susceptibility to all of the tested β-lactams for each of the P. aeruginosa mutant strains. Likewise, antipseudomonal β-lactams (CLSI breakpoints), in combination with 4 or 8 μg/ml of zidebactam or WCK 5153, resulted in enhanced killing. Certain combinations determined full bacterial eradication, even with MDR MBL-producing high-risk clones. β-Lactam–WCK enhancer combinations represent a promising β-lactam “enhancer-based” approach to treat MDR P. aeruginosa infections, bypassing the need for MBL inhibition.